Sanofi (EPA: SAN)
France
· Delayed Price · Currency is EUR 90.90
+0.10 (0.11%)
Nov 21, 2024, 4:25 PM CET
Sanofi Revenue
Sanofi had revenue of 14.16B EUR in the quarter ending September 30, 2024, with 11.49% growth. This brings the company's revenue in the last twelve months to 48.45B, up 6.01% year-over-year. In the year 2023, Sanofi had annual revenue of 46.03B with 1.42% growth.
Revenue (ttm)
48.45B
Revenue Growth
+6.01%
P/S Ratio
2.35
Revenue / Employee
562.74K
Employees
86,088
Market Cap
113.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 46.03B | 644.00M | 1.42% |
| Dec 31, 2022 | 45.39B | 6.21B | 15.86% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | 37.63B | 1.95B | 5.48% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 25.83B |
| Sartorius Stedim Biotech S.A. | 2.74B |
| bioMérieux S.A. | 3.81B |
| Ipsen S.A. | 3.44B |
| Eurofins Scientific SE | 6.72B |
| Virbac SA | 1.34B |
| Ramsay Générale de Santé SA | 5.01B |
| Vetoquinol SA | 537.47M |
Sanofi News
- 3 days ago - Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase - CNBC
- 5 days ago - Vaccine stocks hit by Robert Kennedy Jr nomination - Financial Times
- 5 days ago - European And US Vaccine Stocks Are Under Pressure - Here's WHy - Benzinga
- 6 days ago - Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S. - Seeking Alpha
- 6 days ago - European Stocks Fall as Traders Trim Rate-Cut Bets; Sanofi Drops - BNN Bloomberg
- 6 days ago - Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria - GlobeNewsWire
- 6 days ago - Telangana attracted 141 life sciences investments worth Rs 36,000 crore in 1 year: Sridhar Babu - The Times of India
- 6 days ago - Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom - Benzinga